Back to Feed
ClinicalTrials.gov|Clinical Trial
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
Sclnow Biotechnology Co., Ltd.
Abstract
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period. Phase: PHASE1, PHASE2 Status: SUSPENDED Conditions: Cerebral Infarction Interventions: Allogeneic umbilical cord mesenchymal stem cell; Aspirin Enteric-coated Tablets & Atorvastatin Calcium
Keywords
Cerebral Infarction